About Public Offering
This blog is a natural extension of Columbia Business School's longstanding tradition of innovation and entrepreneurship. read more...
New Healthcare Paradigm: Technology, Value and Emergence
At the 6th Annual Healthcare Conference, industry leaders said they are focused on innovation, value-rich offerings and the emergence of new global markets and technologies.
Rationale and Risks of Merck's $41 Billion Acquisition of Schering-Plough
Yesterday's announcement marks the second time this year that two pharmaceutical giants have agreed to merge. What is driving the consolidation, and what are the risks?
A Perspective on the Pfizer-Wyeth Merger
Why did Pfizer pursue this strategy? And will the acquisition encourage other Big Pharma players to take a similar approach?
Embracing Change in a Challenged Healthcare Industry
At Columbia Business School's 5th Annual Healthcare Conference, industry leaders said they are looking for ways to drive innovation.
What Next For Big Pharma?
As growth slows in the pharmaceutical sector, shareholders are putting pressure on companies and their executives to make some difficult decisions.